ImmunityBio announces early findings from QUILT-106 trial

ImmunityBio (IBRX) announced early findings from its QUILT-106 Phase I trial, showing complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia-a type of non-Hodgkins lymphoma-using its CD19 CAR-NK natural killer cell therapy. QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone and in combination with rituximab in patients with relapsed or refractory CD19 CD20 B-cell NHL. The disease remains challenging to treat, and WM is considered incurable with existing treatment options, making novel immunotherapies an important avenue of exploration for potential effective treatments. In the first two evaluable patients with WM who were heavily pretreated, an entirely chemotherapy-free, immunotherapy regimen induced encouraging responses. Both patients tolerated the regimen with no significant toxicities. Notably, all infusions were administered in an outpatient setting. One patient achieved a complete response with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date. Of the patients enrolled so far, three have WM.